Therefore, this study aimed to target ENT2, i.e., the specific transporter for HPX, using the CRISPR/Cas9 gene-editing tool to determine the role of ENT2 in altered purine metabolism in the early and late stages of CRC cell lines. The gene discussed is HPX; the disease is colorectal carcinoma.